First Tracks BiotherapeuticsTRAX
Recorded

First Tracks Biotherapeutics UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael YeeAnalyst

All right. Good morning, everyone. Thank you so much for joining us on our next session. I'm Michael Yee, Global Head of Biotech Research at UBS, and I'm very excited to have the team from First Tracks Biotherapeutics here with us at the conference, specifically President and Chief Executive Officer Dan Faga up here with us. Dan- Hi, Steve. Mike. Thank you for joining us.

Michael YeeAnalyst

It's a pleasure to have you at our conference.

Dan FagaPresident and CEO

Thank you very much. Nice to be here.

Michael YeeAnalyst

Thank you. Well, let's start with the fact that First Tracks has been putting up some great data with your lead program, a CD122 antagonist antibody, for many autoimmune diseases, but specifically in celiac disease. If I could have you just briefly introduce the company to the audience. Here we are in London, so broadening out the investor base. I would love for you to explain to everybody what ANB033 is and what makes it unique.

Dan FagaPresident and CEO

Thank you very much. Nice to see everyone here today. Representing First Tracks Bio. Yeah First Tracks goes by First Tracks.

Dan FagaPresident and CEO

We have three clinical stage I&I programs within the company, as well as a research platform. We're a new company. We spun out from our predecessor about six, eight months ago. To your point, with our lead program, ANB033, this is a CD122 antagonist for celiac disease and EoE, amongst other targets or indications that we'll be talking about. We did recently announce top line results from our first of two ongoing celiac trials. So really exciting results. First time in the treatments in this disease where there is no approved therapeutics, where we saw an impact both on mucosal injury of celiac disease as well as on symptoms. It's an exciting start to the story here at First Tracks. We have a number of catalysts already lined up for next year across all three of our programs.

Michael YeeAnalyst

Before we get into all three of the programs, let's focus on at least the lead program, of course, which had data recently. There's been a lot of focus on this class because 2026 was the year that three companies, at least, have put up various degrees of phase I data in celiac disease, and all the three molecules are at least somewhat similar in terms of mechanism. Can you explain how you think about the three different programs and how you think about your program as differentiated from the others? Do you think it's better than theirs? Do you think it is more potent? How do you think about that? Argenx just acquired Forte, paid about $2 billion.

Michael YeeAnalyst

$2 billion, and put up some good data in phase I. Teva put up some good data as well, and their stock traded up. In fact, they just had an R&D Day and spent a lot of time talking about this. Tell us about yours, and is your program differentiated and perhaps superior?

Dan FagaPresident and CEO

As these things go, there is a lot of competitive data right now in the space.

Dan FagaPresident and CEO

Yeah. I think when you step back and you look across these three different programs you just cited, we've all had positive data in celiac disease.

Dan FagaPresident and CEO

What I said in my opening remarks, there's nothing approved in celiac disease today. I think we're onto something right now in terms of actually targeting the biology of this disease for the first time directly. Historical approaches generally focused or centered on the targeting of gluten, the antigen Yeah in celiac disease.

Dan FagaPresident and CEO

Yeah. What we do with a CD122 antagonist is we are binding two different T cells that are lit up in this inflammatory cycle.

Dan FagaPresident and CEO

We specifically block the signaling of both IL-15 and IL-2. This is a dual mechanism antagonist.

Dan FagaPresident and CEO

Okay. One of our competitors, argenx, has a similar targeted drug.

Dan FagaPresident and CEO

Okay. Teva is only targeting one of those two cytokines.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day